Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease

Mark F. Lew, Rajesh Pahwa, Maureen Leehey, John Bertoni, Greg Kricorian, Brian H. Avin, Vincent Calabrese, Stewart Factor, Enrico A. Fazzini, Robert A. Hauser, Jean P. Hubble, J. Thomas Hutton, Robert G. Jacoby, John Kelly, Louis C. Kirby, Jack Klapper, William Koller, Jau Shin Lou, Kenneth Marek, Patricia W. NancePaul A. Nausieda, Todd Perkins, Joel Perlmutter, John D. Rogers, Jack D. Schim, Steven M. Sergay, Kapil D. Sethi, Mathew B. Stern, Michael M. Tuchman, Cheryl E. Waters

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease'. Together they form a unique fingerprint.

Medicine & Life Sciences